

Steve Sisolak
Governor



Richard Whitley
Director

State of Nevada
**Department of Health and
Human Services**

Nevada's COVID-19 Vaccine: Governor's Task Force

Division of Public and Behavioral Health
Nevada State Immunization Program



11/9/2020

Helping people. It's who we are and what we do.



Agenda

1. COVID-19 Vaccine Playbook
2. Timeline
3. Vaccine details
4. Phased vaccination strategy
5. Allocation methodology
6. Data reporting
7. Covid-19 Vaccine Confidence

COVID-19 Vaccine Playbook



COVID-19 Vaccination Program
Nevada's Playbook for
Statewide Operations


NEVADA STATE IMMUNIZATION PROGRAM; DIVISION OF PUBLIC & BEHAVIORAL HEALTH; DEPARTMENT OF HEALTH AND HUMAN SERVICES

<https://nvhealthresponse.nv.gov/wp-content/uploads/2020/10/COVID-19-Vaccination-Program-Nevadas-Playbook-for-Statewide-Operations.pdf>



Timeline

The COVID-19 Vaccination Program will require a phased approach



9/4/20

*Planning should consider that there may be initial age restrictions for vaccine products.

**See Section 4: Critical Populations for information on Phase 1 subset and other critical population groups.





COVID-19 Vaccine Details

- Two vaccines first: one frozen, one ultra-cold (-70°C)
 - This is where we are focusing much of our planning efforts right now.
- 6 vaccines currently in production and in contract with the United States Government.
 - 5 of the 6 vaccines are two-dose series.
- Limited federal facilities and corporate pharmacies will receive their own allocation of COVID-19 vaccine.
 - Tribal jurisdictions can choose to receive federal or state allocation.
- All other immunizing providers must be enrolled in the Pandemic Provider Program.
 - These providers will order vaccine from or be allocated vaccine from NSIP.





COVID-19 Vaccine Details

- Vaccine will be limited at the beginning.
- Initial vaccine will likely be an Emergency Use Authorization (EUA) vaccine.
- Vaccine allocation will likely increase quickly through 2020 and be ready for vaccination of general population by early to mid 2021.



Timeline details

- The Nevada State Immunization Program has been told by the CDC to be ready by mid-November.
- Pfizer (ultra-cold) will likely be first.
 - Current timeline indicates beginning of December
- Other vaccines will likely follow closely
 - Moderna likely towards the end of December



Phased Vaccination Strategy

- Starting with frontline healthcare workers, then the rest of the healthcare workers
- Critical infrastructure workforce
- Nevadans living in congregate settings, those experiencing homelessness
- Nevadans who are 65 years and older and those who have underlying or comorbid health conditions
- General public
- No pregnant women or children at this time



Criteria for phased populations

- 1) Level of exposure to COVID-19
 - a. Population has unavoidable, close contact with those who may have COVID-19
- 2) Length of exposure
 - a) Population has unavoidable, sustained contact with those who may have COVID-19
- 3) Importance of job/special technical skill
 - a) Population has special technical skill that is not easily replaced (i.e. doctor, meat packing plant employee, utility worker, teacher)
 - b) Population has a job that others in the community depend on for overall community safety and well-being
- 4) Likelihood of increasing community spread
 - a) Populations that would increase spread within the community or within a closed, residential facility
- 5) Mortality rate
 - a) Population has increased likelihood of death from COVID-19
- 6) Morbidity rate
 - a) Population has increased likelihood of COVID-19 infection
- 7) Immune response
 - a) Vaccine shown to provide a proper immune response in the population vaccination (e.g. older people often do not show a strong immune response to vaccination)

Allocation

- Methodology approved by the Governor's COVID-19 Mitigation and Management Task Force to monitor county-level disease transmission. A county is flagged for elevated disease transmission if it meets two of the three criteria:
 1. **Average number of tests per day (per 100,000) < 100.**
 2. **Case rate (per 100,000) > 200.**
 3. **Case rate (per 100,000) > 50 AND testing positivity > 8.0%.**
- Using these established criteria, NSIP will determine which counties are experiencing elevated disease transmission.
- Allocation criteria will look different for hospitals.
 - Will focus on COVID-19 patients and bedcounts



Nevada's Current Status

- Currently enrolling Local Health Authorities, rural community health nursing offices, acute care hospitals, and any other provider identified to serve healthcare workers and frontline personnel.
- Current efforts are extremely focused.
 - Joint decisions





Being Prepared to Collect/Report COVID-19 Vaccination Data

- NV WebIZ (statewide immunization information system – IIS) is primary tool
 - Vaccine ordering & documentation
 - Reminders for 2nd dose
- Vaccine administration data must be reported to CDC every 24 hours.



Vaccine Clinical Trials

How a new vaccine is developed, approved and manufactured

The Food and Drug Administration (FDA) sets rules for the three phases of clinical trials to ensure the safety of the volunteers. Researchers test vaccines with adults first.

PHASE 1




**20-100
healthy volunteers**



- Is this vaccine safe?
- Does this vaccine seem to work?
- Are there any serious side effects?
- How is the size of the dose related to side effects?

PHASE 2



**several hundred
volunteers**

- What are the most common short-term side effects?
- How are the volunteers' immune systems responding to the vaccine?

PHASE 3




**hundreds or thousands
of volunteers**

- How do people who get the vaccine and people who do not get the vaccine compare?
- Is the vaccine safe?
- Is the vaccine effective?
- What are the most common side effects?



OPERATION WARP SPEED ACCELERATED VACCINE PROCESS

MISSION: Deliver 300 million doses of safe and effective vaccine by 1 January 2021.





Financial
Risk Is
Okay;
Safety Risk
Is NOT

- Operation Warp Speed is manufacturing vaccine concurrently with clinical trials with the intention of disposing of the vaccine if it is not safe and/or effective.



COVID-19 Vaccine Clinical Trials

- Independent review boards
 - Data Safety Monitoring Board
 - FDA: Vaccine and Related Biologic Product Advisory Committee
 - CDC: Advisory Committee on Immunization Practices
- Same approval process as childhood, influenza, and other traditional vaccines.
 - Be confident in the public health and medical system.

Key takeaways

- There is an equitable and science-based plan to distribute COVID-19 vaccine to Nevadans.
- There is an existing vaccine distribution infrastructure in the state of Nevada.
- COVID-19 vaccine clinical trial processes will only allow for a safe and effective COVID-19 vaccine to be released for use.



Questions?





Contact Information

Shannon Bennett

Manager, Nevada State
Immunization Program

sbennett@health.nv.gov

775-350-5261

Candice McDaniel

Chief, Bureau Child, Family, and
Community Wellness

cmcdaniel@health.nv.gov

775-515-5234

